Experts back generic drug push for Spinal Muscular Atrophy, citing 97% cost reduction

Health experts and public health activists have supported the state government's decision to replace the branded drug for Spinal Muscular Atrophy (SMA) with a low-cost generic alternative. They cited a price reduction of approximately 97%, noting that Natco’s generic version of risdiplam costs Rs 15,900, compared to the branded drug's cost of Rs 6.2 lakh per bottle. Dr B Ekbal, a former professor of neurosurgery, stated that the court ruled in October 2025 in favor of allowing the generic formulation, dismissing claims of inadequate bioavailability.